Should Clinics Prescribe Medicinal Cannabis that They Also Supply? We Asked 5 Experts
Australian medicinal cannabis prescriptions have exploded, driven by convenient online consultations and one‑stop‑shop models that combine prescribing with dispensing. Critics label this vertical integration a conflict of interest, arguing that clinics may prioritize profit over patient safety and prescribe unapproved products. Five leading experts unanimously advised against allowing clinics to both prescribe and supply cannabis, citing clinical, ethical, and regulatory concerns. The debate now centers on how regulators will curb profit‑driven prescribing while preserving patient access.
White House Adds AbbVie's Humira to TrumpRx Alongside Cheaper Biosimilars
The White House’s drug‑discount portal TrumpRx now lists AbbVie’s Humira at $950 per month, a steep cut from its typical $5,000‑plus price. The listing appears alongside two lower‑cost biosimilars that target the same inflammatory conditions. TrumpRx aims to provide seniors...
Newly Developed Smart Molecules Offer a Safer and More Precise Approach to Cancer Care
Researchers at NYU Abu Dhabi have created manganese‑based smart molecules that act as both MRI contrast agents and cancer therapeutics. The compounds stay inert in healthy tissue and activate in the acidic micro‑environment of tumors, releasing manganese ions that enhance...
Outcomes of Treatment for Methicillin-Resistant Staphylococcus Aureus Ventilator-Associated Pneumonia
A retrospective study of 125 patients with MRSA‑associated ventilator‑associated pneumonia compared trimethoprim‑sulfamethoxazole (SMX‑TMP) to the standard vancomycin therapy. Mortality was 28% with SMX‑TMP versus 37% with vancomycin, a difference that was not statistically significant. Clinical cure rates at day 5 and...
Combination of Ranibizumab, Dexamethasone Superior to Ranibizumab Alone for Macular Edema
A retrospective real‑world study of 139 eyes with non‑ischemic retinal vein occlusion‑related macular edema found that sequential ranibizumab followed by a dexamethasone implant yielded superior visual outcomes compared with three monthly ranibizumab injections alone. At three months, the combination group...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Researchers at Westlake University unveiled a high‑throughput yeast‑surface‑display platform to engineer fast‑acting covalent protein therapeutics. The system screens diverse crosslinkers and millions of protein variants, enabling precise spatial positioning of warheads that dramatically speeds covalent bond formation. Using the platform,...
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities
U.S. drugmaker Gilead Sciences announced a definitive agreement to acquire German ADC specialist Tubulis for up to $5 billion, including $3.15 billion upfront cash and up to $1.85 billion in milestones. The acquisition brings Tubulis’ next‑generation antibody‑drug conjugate platform, highlighted by the TUB‑040...
Pulsed Intra-Arterial Infusion with Synchronously Controlled Blood Flow: A Novel Strategy for Optimizing Intra-Arterial Chemotherapy
Researchers introduced a pulsed intra‑arterial infusion technique with synchronized blood‑flow control (PBC‑IA) to improve chemotherapy delivery. In rabbit models, the method produced more than 20‑fold higher doxorubicin concentrations in the target gastrocnemius muscle compared with standard intravenous injection, while heart...
Gilead Buys Tubulis to Boost ADC Platform
Gilead Sciences announced a definitive agreement to acquire Germany‑based Tubulis for up to $5 billion, adding a clinical‑stage antibody‑drug conjugate (ADC) pipeline and a next‑generation linker‑payload platform. The deal brings Tubulis’ lead candidate TUB‑040, a NaPi2b‑targeting ADC in phase 1b/2 for platinum‑resistant...
Terns Rebuffed a Higher Bid Before Selling to Merck
Terns Pharmaceuticals accepted Merck & Co.'s $53‑per‑share, $6.7 billion buyout, a price roughly 15% below an earlier $61 offer from an unnamed Party C. Party C’s proposal included a contingent $9‑per‑share payout tied to FDA approval of TERN‑701, but it withdrew after updated...
Semaglutide Improves Kidney, Survival Outcomes Along CKD Spectrum
Semaglutide (Ozempic) significantly lowered the risk of kidney failure and all‑cause mortality in the FLOW trial, which enrolled 3,533 type‑2 diabetes patients with chronic kidney disease. The drug reduced the primary composite kidney outcome by 24% (HR 0.76) and cut overall...
Regulatory Actions for April 7, 2026
On April 7, 2026 regulators issued several high‑profile decisions across biopharma and medical‑technology. Allevion secured FDA clearance for its next‑generation gene‑therapy platform, Regeneron obtained EMA approval for a monoclonal antibody targeting a rare autoimmune disorder, and Stereotaxis earned a CE...
Kennedy Sidestepping Court Order Sidelining ACIP?
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
South Korea Streamlines Biosimilar Review, Clinical Trials
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
Gilead Buying Tubulis and Its ADCs in $5B Takeover Bid
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu Wins $5.2M ARPA-H Grant for Ultrasound-Activated Therapeutics
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Amplia Halts Enrollment in Phase II Pancreatic Cancer Trial
Amplia Therapeutics announced it is halting enrollment in its phase II trial of the investigational pancreatic cancer agent after an interim safety review revealed concerning signals and modest efficacy. The study, which began enrolling patients in early 2025, was designed to...
Development of Emerging Modalities: Challenges and Strategies
The article outlines that emerging therapeutic modalities—such as antibody‑drug conjugates, multispecific antibodies, viral vectors, gene‑editing and RNA‑based medicines—present far greater molecular and manufacturing complexity than traditional biologics. Four primary hurdles are identified: structural heterogeneity, absence of universal platform processes, difficulty...
Other News to Note for April 7, 2026
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
In the Clinic for April 7, 2026
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
Best of BioWorld: Q1
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...
Financings for April 7, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without motor side effects, and plan IND‑enabling studies later this year. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, fostering leukemic...
ARPA-H Selects Three Teams in $100M Effort to Repair and Regrow Ailing Joints
ARPA-H announced a $100 million program to fund clinical trials for joint regeneration. Three leading academic centers were selected to test innovative therapies aimed at repairing and regrowing damaged cartilage and bone. The projects will explore senolytic drugs, engineered tissue scaffolds,...
Gilead Continues M&A Surge with $3.1B Deal for ADC Specialist Tubulis
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Terns Sold to Merck for 13% Lower than Pharma's Initial Offer because of Clinical Data
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, a price roughly 13% lower than its initial offer after new clinical data raised concerns. The renegotiated deal reflects the impact of late‑stage trial results on valuation in the biotech M&A wave....
Novo Launches High-Dose Wegovy in the US; Evotec Pressured to List Its US Unit
Novo Nordisk has introduced a high‑dose 7.2 mg version of its obesity drug Wegovy in the United States, expanding the GLP‑1 portfolio beyond the standard 2.4 mg dose. The new formulation targets patients with severe obesity who need greater weight‑loss efficacy. Pricing...
Robin Weiss Obituary
Robin Weiss, a pioneering virologist who died at 86, led the 1984 discovery that CD4 is the cellular receptor for HIV and created the first UK HIV antibody test with Richard Tedder. The test enabled large‑scale, accurate detection of HIV,...
Sector Tariff Now More than a Threat – for some Rx Companies
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that demonstrate potent pre‑clinical analgesic activity for chronic neuropathic pain. New research links chronic inflammatory signaling to early leukemic transformation in hematopoietic stem cells, suggesting anti‑inflammatory approaches could intervene before disease...
Biopharma Financings Nearly Double Vs. 2025 to $25.1B
Biopharma financing in 2026 surged to $25.1 billion, almost twice the amount raised in 2025. The jump reflects a wave of venture‑capital commitments, a robust IPO market, and heightened merger‑and‑acquisition activity. Public offerings alone added roughly $8 billion, while private rounds supplied...
Five-Drug VIPOR Regimen Shows Promise in Aggressive Blood Cancer
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without cardiac or CNS effects, and plan IND‑enabling toxicology studies in 2026 with Phase I trials slated for 2027. Parallel advances in hematopoietic...
Autoimmune Disease-Related Inflammation Reduced with ENDOtollins Drug
A study in *Nature Chemical Biology* reports a new class of compounds called ENDOtollins that selectively block the Munc13‑4–syntaxin 7 interaction, dampening endosomal Toll‑like receptor activation and systemic inflammation. Screening of roughly 32,000 molecules identified ENDO12 as the most potent candidate,...
Why Timelines Break Down in Rare Kidney Drug Development
Enrollment bottlenecks are the dominant cause of delays in kidney‑focused drug development. GlobalData data show low accrual rates drive 47% of nephrology trial suspensions, while median enrollment stretches beyond 15 months—far longer than cardiovascular or metabolic studies. Typical renal trials...
Gilead Outlays $5bn to Acquire ADC Specialist Tubulis
Gilead announced a deal to acquire German ADC specialist Tubulis for up to $5 bn, with $3.15 bn paid upfront and up to $1.85 bn in milestones. The transaction, slated to close in Q2 2026, brings Tubulis' lead candidate TUB‑040—a NaPi2b‑directed topoisomerase‑I inhibitor in...
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
GLP‑1 drugs have dominated obesity and diabetes treatment, but side effects and muscle loss are prompting a search for alternatives. Amylin analogs—long‑acting peptides that mimic the hormone amylin—are re‑emerging, with Novo Nordisk’s CagriSema, Lilly’s eloralintide, Roche’s petrelintide and others showing...
HexemBio Raises $10.4M Seed for Stem Cell Rejuvenation
HexemBio announced a $10.4 million seed round, led by Draper Associates with participation from SOSV, Seraphim and other investors. The biotech is developing a Synthetic Human Yolk Sac that temporarily houses a patient’s blood stem cells to rejuvenate their function before...
A Common Antidepressant Shows Promise in Treating Methamphetamine Dependence
A new JAMA Psychiatry study shows the antidepressant mirtazapine can modestly reduce methamphetamine use. In the double‑blind Tina Trial, 339 Australian participants received either 30 mg daily mirtazapine or placebo for 12 weeks. Those on mirtazapine cut meth use by an...
Tech Transfer Powered by Dual Site Precision
Rentschler BioPharma uses a coordinated dual‑site manufacturing model to streamline tech transfers from development to GMP production. By aligning timelines early, defining critical parameters, and managing equipment differences, the company accelerates transfer schedules while preserving product quality. The approach leverages...
The Price Americans Pay for Medicine Has Gotten Horribly Out of Control. Here’s How to Fix It.
Humira, AbbVie’s adalimumab used by over 300,000 Americans, continues to dominate the market even after its patent expired, keeping prices sky‑high. The drug’s outsized share illustrates systemic flaws in U.S. pharmaceutical distribution, where limited biosimilar competition and opaque pricing inflate...
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
AbbVie has agreed to sell its blockbuster arthritis drug Humira on the Trump administration’s direct‑to‑consumer platform TrumpRx for about $950, an 86 % cut from the typical $6,900 out‑of‑pocket price. The deal, announced after AbbVie pledged $100 billion in R&D and manufacturing...
STAT+: Pharmalittle: We’re Reading About FDA Backing Domestic Production, Another Gilead Deal, and More
The FDA, leveraging the Trump administration’s budget, unveiled proposals to boost domestic drug development and manufacturing, including streamlined early‑stage trials and a rule letting U.S. generic makers challenge brand patents a month before foreign competitors. Commissioner Marty Makary framed the...
Gilead Acquires German ADC Specialist Tubulis in US$5bn Deal
Gilead Sciences agreed to acquire German ADC specialist Tubulis for up to US$5 bn, including a US$3.15 bn cash upfront payment and up to US$1.85 bn in milestones. The deal brings Tubulis’s proprietary antibody‑drug conjugate platforms and two late‑stage assets—TUB‑040, a NaPi2b‑targeted topoisomerase‑I...
Key Biosimilars Events of March 2026
March 2026 saw a surge of biosimilar activity, highlighted by Celltrion’s launch of Remsima IV in the EU and Avtozma SC in the United States, expanding both IV and sub‑cutaneous options for infliximab and tocilizumab. Samsung Bioepis inked a global...
FDA-Approved Drug Manufacturing Deals Shift to Europe
In 2025, U.S. contract manufacturing deals for FDA‑approved drugs fell sharply, while Europe recorded more than three times the U.S. volume. Despite a 15% U.S. tariff on EU pharmaceuticals, major U.S. firms such as Johnson & Johnson and Vertex invested...
Matcha Model Makes Drug Candidate Screening More than 30 Times Faster
Ligand Pro’s Matcha model, an AI‑driven molecular docking system, can screen drug candidates more than 30 times faster than AlphaFold 3 while maintaining comparable accuracy and greater physical realism. The algorithm processes a protein‑ligand complex in just 13 seconds, turning months‑long virtual screens into...
HexemBio Raises $10.4M for a Stem Cell Rejuvenation Therapy
HexemBio announced a $10.4 million seed round led by Draper Associates to develop a blood‑stem‑cell rejuvenation therapy built on its Synthetic Human Yolk Sac platform. The technology temporarily places a patient’s own haematopoietic cells into a recreated embryonic niche, then returns...
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
The FDA is requesting new legislative authority to enforce post‑approval manufacturing changes, including major facility or active pharmaceutical ingredient (API) supplier switches. The proposal, part of the FY 2027 budget, would amend the 1997 FD&C Act to require validation and approval...
The Future of Cell & Gene Therapy: Key Trends to Watch
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
From Low Yields to High Efficiency: Modernizing Complex Biologics Manufacturing
WuXi Biologics hosted a webcast detailing an integrated platform that can boost yields of complex biologics up to six‑fold while cutting manufacturing costs by as much as 80%. The approach combines platform‑based media optimization, cell‑culture intensification via WuXiUI™, downstream capacity...
From PC to CPV: Preserving Process Knowledge Through Late‑Phase Tech Transfer
Catalent’s Danielle Wittenwyler, PhD, will host a webinar on preserving years of process characterization (PC) during late‑phase tech transfers. She outlines a structured, risk‑based methodology that translates sponsor‑generated PC into Catalent’s Madison facility while maintaining design‑space intent. The approach identifies...
Orexin OX2 Receptor Agonists Disclosed in Vertex Pharmaceuticals Patent
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...